Skip to main content
Log in

Clinical Experience with Growth Hormone Treatment in Patients with β-Thalassaemia Major

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The aetiology of the growth retardation occurring in patients with β-thalassaemia major is considered to be multifactorial. Although growth hormone (GH) secretion appears to be normal in many thalassaemic patients with short stature, there is evidence indicating impaired GH secretion in approximately 3% of patients. The response to recombinant human GH treatment (rHGH) is not predictable, based on either the parameters known to affect the response to treatment or the type of defect in the GH-insulin-like growth factor (IGF-1) axis. The wide variation in growth velocity observed during rHGH treatment suggests that treatment with the usual dose of rHGH (0.6 U/kg/week) cannot be considered effective in all patients, although rHGH has been successful in some patients. Therefore further studies are required in order to evaluate the effects of supraphysiological doses of rHGH on growth. Since these patients are prone to develop abnormal glucose homeostasis, oral glucose tolerance tests must be performed periodically during rHGH treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fessas P, Loukopoulos D. The beta-thalassaemias. Clin Haematol 1974; 3: 411–35

    Google Scholar 

  2. Wonke B. Management of beta-thalassaemia major. Curr Paediatr 1994; 4: 38–42

    Article  Google Scholar 

  3. Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia major. Cooley care programme. Lancet 1991; 337: 277–80

    Article  PubMed  CAS  Google Scholar 

  4. DeSanctis V, Wonke B. Growth in thalassaemia. Farmaci 1994 Suppl.: 1-45

  5. Bergeron C, Kovacs K. Pituitary and ultrastructural study. Am Pathol 1978; 93: 292–309

    Google Scholar 

  6. De Sanctis V, Atti G, Banin P, al. Growth in thalassaemia major. Acta Med Auxol 1991; 23: 29–36

    Google Scholar 

  7. De Sanctis V, Stea S, Savarino L, et al. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Pediatr Endocrinol Metab 1998; 11(5): 227–33

    Google Scholar 

  8. Vassilopoulou-Sellin R, Oyedejico, Foster PL, et al. Hemoglobin as a direct inhibitor of cartilage growth in vitro. Horm Metabol Res 1989; 21: 11–4

    Article  CAS  Google Scholar 

  9. De Virgilis S, Congia S, Frau M, et al. Deferioxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 113: 661–9

    Article  Google Scholar 

  10. De Sanctis V, Urso L, Galati MC, et al. Growth hormone (GH) treatment in thalassamic patients with short stature, GH insufficiency and different severity of iron overload. Bone Marrow Transplant 1997; 19: 32–3

    Google Scholar 

  11. Vullo C, De Sanctis V, Katz M, et al. Endocrine abnormalities in thalassaemia. Ann N Y Acad Sci 1990; 612: 293–310

    Article  PubMed  CAS  Google Scholar 

  12. Pintor G, Cella SG, Manso P, et al. Impaired growth hormone (GH) response to GH-releasing hormone in thalassaemia major. J Clin Endocrinol Metab 1986; 62; 263–7

    Article  PubMed  CAS  Google Scholar 

  13. Shehadeh N, Hazani A, Rudolf MCJ, et al. Neurosecretory dysfunction of growth hormone secretion in thalassaemia major. Acta Paediatr Scand 1990; 79: 790–5

    Article  PubMed  CAS  Google Scholar 

  14. Saenger P, Schwartz E, Markenson AL, et al. Depressed serum somatomedin activity in beta-thalassaemia. J Pediatr 1980; 96: 214–8

    Article  PubMed  CAS  Google Scholar 

  15. Werther GA, Nathews RN. Burger HG, et al. Lack of response of non-suppressible insulin-like activity in thalassaemia major. J Clin Endocrinol Metab 1981; 53: 806–9

    Article  PubMed  CAS  Google Scholar 

  16. Herrington AC, Werther GA, Mathews RN, et al. Studies on the possible mechanism for deficiency of nonsuppresible insulinlike activity in thalassaemia major. J Clin Endocrinol Metab 1981; 52: 393–8

    Article  Google Scholar 

  17. De Sanctis V, Pintor C, Gamberini MR, et al. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol 1995; 42: 581–6

    Article  Google Scholar 

  18. De Luca G, Maggiolini M, Bria M, et al. Valutazione della secrezione dell’ormone della crescita (GH) in soggetti affetti da thalassemia major. Minerva Endocrinol 1993; 18 Suppl.: 62–5

    PubMed  Google Scholar 

  19. Di Martino J, Stoner E, Giardina PJ, et al. Effect of exogenous growth hormone in patients with thalassaemia major [abstract]. Pediatr Res 1985; 80: 900

    Google Scholar 

  20. Scacchi M, Danesi L, De Martin M, et al. Treatment with bio-synthetic growth hormone of short thalassaemic patients with impaired growth hormone secretion. Clin Endocrinol 1991; 35: 335–9

    Article  CAS  Google Scholar 

  21. Theodoridis C, Karis C, Ladis V, et al. Effects or recombinant human growth hormone on growth of thalassaemic children with G.H.D [abstract]. World Congress of Pediatrics; 1992 Jun 12-15; Rio de Janeiro, Brazil; 55: T914–11

    Google Scholar 

  22. Caruso-Nicoletti M, Mancuso M, Spadaro G, et al. Response to growth hormone treatment in thalassaemic patients [abstract]. 10th International Congress of Endocrinology (ICE ’96); 1996 Sep 12-15; San Francisco: 765: P3–43

    Google Scholar 

  23. De Sanctis V, Urso L. L’accrescimento staturale nella talassemia. Minerva Pediatr 1997; 47: 121–8

    Google Scholar 

  24. Theodoridis C, Papatheodorou A, Karis C, et al. Short and long-term effect of rhGH on growth of short GH deficiency children with beta-thalassaemia [abstract]. 34th Annual Meeting of ESPE, Edinburgh. Horm Res 1995 Jun 25-28; 58: 228

    Google Scholar 

  25. Masala A, Alagna, S, Gallisai D, et al. GH secretion after bone marrow transplantation (BMT) in patients with homozygous beta-thalassaemia. J Clin Endocrinol Invest 1992; 15 Suppl. 1: 126

    Google Scholar 

  26. Low WK, Kwan EYW, Lim YJ, et al. Growth hormone treatment of short Chinese children with beta-thalassaemia major without GH deficiency. Clin Endocrinol 1995; 42: 359–63

    Article  CAS  Google Scholar 

  27. Low LCK. Growth, puberty and endocrine function in beta-thalassaemia major. J Ped Endocrinol Metab 1997; 10: 175–84

    CAS  Google Scholar 

  28. Frasier SD. Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev 1983; 4: 155–60

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Sanctis, V., Urso, L. Clinical Experience with Growth Hormone Treatment in Patients with β-Thalassaemia Major. BioDrugs 11, 79–85 (1999). https://doi.org/10.2165/00063030-199911020-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-199911020-00002

Keywords

Navigation